Towards an adiposity-related disease framework for the diagnosis and management of obesities.

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.

Time-varying association of acute and post-acute COVID-19 with new-onset diabetes mellitus among hospitalized and non-hospitalized patients.

European Association for the Study of Obesity Position Statement on Medical Nutrition Therapy for the Management of Overweight and Obesity in Adults Developed in Collaboration with the European Federation of the Associations of Dietitians.

Obesity is a chronic progressive relapsing disease of particular interest for internal medicine.

Physicians' responsibility toward environmental degradation and climate change: A position paper of the European Federation of Internal Medicine.

Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months.

Assessing Obesity-Related Adipose Tissue Disease (OrAD) to Improve Precision Medicine for Patients Living With Obesity.

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.

Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement.

EAES rapid guideline: systematic review, network meta-analysis, CINeMA and GRADE assessment, and European consensus on bariatric surgery-extension 2022.

Pulmonary embolism - An EFIM guideline critical appraisal and adaptation for practicing clinicians.

miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.

Gastrointestinal tolerability of once-weekly semaglutide 2.4Â mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.